Genevant Sciences and Arbutus Biopharma jointly filed five international lawsuits against Moderna, Inc. and its affiliates, targeting alleged patent infringement in 30 countries. The lawsuits seek monetary relief and injunctions related to Moderna's Spikevax® and mRESVIA® products.
The legal actions assert that Moderna's mRNA vaccines utilize Arbutus and Genevant's proprietary lipid nanoparticle (LNP) technology without proper licensing. Evidence from commercial Moderna product samples was submitted, indicating the use of LNPs falling under the protective scope of their lipid composition patents.
These international filings expand upon an existing U.S. lawsuit against Moderna in the District Court for the District of Delaware, where a jury trial is scheduled for September 2025. The LNP technology is described as crucial for safely and effectively delivering RNA molecules.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.